History
-
2016 Year- Established in 2016 with successful angel round financing.
-
2017 Year
- Launched GMP cell laboratory in 2017.
-
2018 Year
- Achieved the first super donor hiPSC from the Chinese population;
- Undertook the special project of "Standardized Research on Stem Cell Preparations and Applications" under the National Key Research and Development Program of the Ministry of Science and Technology of the People's Republic of China.
-
2019 Year
- Accelerate the research and development process of various cell therapy pipelines.
-
2020 Year
- Establish a super donor hiPSC bank for the Chinese population, which can cover more than 50% of the Chinese population.
-
2021 Year
- Undertake the special project of "Quality Control and Evaluation Technology of Stem Cells and Related Products" under the National Key Research and Development Program of the Ministry of Science and Technology.
-
2022 Year
- The IND of the first domestic iPSC - derived iMSC cell therapy was approved;
- Hundreds of millions of yuan in Series A financing was completed.
-
2023 Year
- The IND application for the first iPSC - derived iNK cell therapy in China was approved;
- The IND application for a new indication of the iNK cell therapy was approved.
-
2024 Year
- Was honored as a national specialized and sophisticated "little giant" enterprise；
- iMSC (KOA) —— Phase I clinical tria；
- iNK (MDS) —— Phase I clinical trial；
- iNK ( AML) —— Phase I/II clinical trial；
- Several pipelines have completed the IND registration declaration.
-
2025 Year
-
iMSC (KOA) —— Phase II clinical trials；
-
Gene-modified iMSC (ILD) —— Phase I/II clinical trials；
-
iMSC (SR-aGvHD) —— Phase I/II clinical trials；
-
Series B financing —— RMB 235 million completed；
-
Continuously updated...
-